Argenica Therapeutics Limited (ASX:AGN)

Argenica Therapeutics Income Statement

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022
Other Revenue	5.7	3.21	2.6	1.75	0.26
Revenue	5.7	3.21	2.6	1.75	0.26
Revenue Growth	77.26%	23.70%	48.46%	575.38%	-12.49%
Gross Profit	5.7	3.21	2.6	1.75	0.26
Selling, General & Admin	2.82	2.65	2.11	1.86	1.43
Research & Development	4.21	8.13	6.02	4.31	2.5
Operating Expenses	7.06	10.9	8.27	6.62	4.35
Operating Income	-1.37	-7.68	-5.67	-4.87	-4.09
Interest Expense	-0	-0	-0	-0	-0
Interest & Investment Income	-	0.51	0.19	0.06	0
Pretax Income	-1.37	-7.17	-5.48	-4.82	-4.09
Net Income	-1.37	-7.17	-5.48	-4.82	-4.09
Net Income to Common	-1.37	-7.17	-5.48	-4.82	-4.09
Net Income Growth	-	-	-	-	-
Shares Outstanding (Basic)	124	128	104	74	74
Shares Outstanding (Diluted)	124	128	104	74	74
Shares Change	-2.67%	22.97%	40.29%	-	108.80%
EPS (Basic)	-0.01	-0.06	-0.05	-0.07	-0.06
EPS (Diluted)	-0.01	-0.06	-0.05	-0.07	-0.06
EPS Growth	-	-	-	-	-

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-23.96%	-239.05%	-218.30%	-278.59%	-1579.49%
Profit Margin	-23.97%	-223.12%	-210.92%	-275.16%	-1578.84%
EBIT	-1.37	-7.68	-5.67	-4.87	-4.09
EBIT Margin	-23.96%	-239.05%	-218.30%	-278.59%	-
Revenue as Reported	5.7	3.73	2.79	1.81	0.26

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Aug 26, 2026

Data Sources Report a data error